949 results on '"Schicha, H."'
Search Results
152. Benigne Schilddrüsenerkrankungen, Radioiodtherapie und Diagnosis Related Groups (DRGs): Kosten-Nutzen-Aspekte
153. Guideline for radioiodine therapy for benign thyroid diseases (version 3)
154. Overtherapy or undertherapy for papillary thyroid microcarcinoma?
155. 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases
156. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)
157. Lifetime follow-up care is necessary for all patients with treated thyroid nodules
158. Reimbursement of the PET in oncology in Europe: a questionnaire based survey
159. 18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer
160. Hodgkin’s lymphoma in nuclear medicine: diagnostic and therapeutic aspects
161. Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2)
162. PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer
163. Prevention, screening and therapy of thyroid diseases and their cost-effectiveness
164. Procedure guideline for thyroid scintigraphy (version 2)
165. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2)
166. Procedure guideline for radioiodine test (version 2)
167. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage
168. Klinische Wertigkeit der FDG PET in der Diagnostik gynäkologischer Tumoren: Empfehlungen der dritten Deutschen Interdisziplinären Konsensuskonferenz, „Onko-PET III“
169. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma
170. Assessment of endocrine disorders of the hypothalamicpituitary axis by nuclear medicine techniques
171. Body weight gain after radioiodine therapy of hyperthyroidism
172. Graves’ disease and toxic nodular goiter – radioiodine therapy
173. Die neue Strahlenschutzverordnung aus der Sicht des Nuklearmediziners an der Klinik
174. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
175. Comparison of dobutamine-stress magnetic resonance imaging and dipyridamole-Tl-201-SPECT as alternative strategies for the detection of coronary artery disease in patients not suitable for stress-echocardiography
176. High Cervical Spinal Cord Stimulation (CSCS) Increases Regional Cerebral Blood Flow After Induced Subarachnoid Haemorrhage in Rats
177. Radioiodine therapy of Graves’ disease — a dosimetric comparison of different strategies concerning antithyroid drugs
178. Exhalation of 1-131 after radioiodine therapy: time dependence and chemical form
179. Influence of stable iodine on the uptake of the thyroid – model vs. experiment
180. Cost-effectiveness of PET for the management of lung tumours: Comparison of economic data
181. Der Einfluß physiologischer und pharmakologischer Iodmengen auf den I-Uptake der Schilddrüse – Eine Modellrechnung
182. Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PET
183. Incorporation Risks for Workers in PET Centres
184. Single-channel activity and expression of atrial L-type Ca2+channels in patients with latent hyperthyroidism
185. Metastasiertes follikuläres Schilddrüsenkarzinom mit intrakranieller lod-131-Anreicherung in einem Hirnödem bei frontalem Meningeom
186. Influence of iodine application during radioiodine therapy in case of impending therapy failure
187. Determination of the thyroid volume by ultrasonography – comparison with surgical facts
188. Synthese tumoraffiner Yb-169- und Y-90-Porphyrin-Komplexe und tierexperimentelle Untersuchung verschiedener Yb-169-Porphyrine
189. Kosten-Effektivitäts-Analyse: Radioiod oder thyreostatische Medikation bei der Primärbehandlung der Immunhyperthyreose
190. D3: ANTITHYROID DRUGS OR RADIOIODINE AS FIRST-LINE THERAPY OF GRAVES' HYPERTHYROIDISM IN A COUNTRY WITH STRICT REGULATIONS FOR RADIATION PROTECTION?
191. F-18-FDG-PET bei Schilddrüsen-Autonomien
192. Zweizeitige Radioiodtherapie benigner Schilddrüsenerkrankungen während eines stationären Aufenthaltes – Beobachtungen an 100 Patienten
193. Glucose Metabolism of the Thyroid in Graves' Disease Measured by F-18-Fluoro-Deoxyglucose Positron Emission Tomography
194. Verschlechterung einer endokrinen Orbitopathie nach Radioiodtherapie bei M. Basedow?
195. Gleichzeitiges Auftreten einer endokrinen Orbitopathie und einer Schilddrüsenautonomie
196. Strahlenexposition Angehöriger von Patienten nach stationärer Radioiodtherapie durch Inhalation von 131I in der Wohnung
197. Auswirkungen der neuen Entlassungsrichtwerte auf die Kostenstruktur der Radioiodtherapie
198. Follow-up of Differentiated Thyroid Cancer: What is the Value of FDG and Sestamibi in the Diagnostic Algorithm?
199. Die Kinetik von rezeptorvermittelter Radiotoxizität des 16α-[125I]-Iodöstradiol-3,17ß
200. Einfluß von Krankheitsprognose und Alter auf das Strahlenrisiko durch nuklearmedizinische Diagnostik (am Beispiel der Skelettszintigraphie)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.